Direct factor Xa inhibition attenuates acute lung injury progression via modulation of the PAR-2/NF-κB signaling pathway

Meng Shi1,3*, Linlin Wang2,3*, Jian Zhou2,3, Shimeng Ji2,3, Ningfang Wang2,3, Lin Tong2,3, Jing Bi2,3, Yuanlin Song2,3, Jie Hu2,3, Xiaofeng Chen1

1Department of Cardiothoracic Surgery, Huashan Hospital, Fudan University, Shanghai, China; 2Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China; 3Shanghai Respiratory Research Institution, Shanghai, China. *Co-first authors.

Received March 12, 2018; Accepted June 23, 2018; Epub August 15, 2018; Published August 30, 2018

Abstract: The role of coagulation in acute lung injury (ALI) remains unclear. As factor Xa-dependent protease-activated receptor 2 (PAR-2) is reported to be an important target in blood coagulation and other processes, an inhibitor of factor Xa, rivaroxaban, was tested in vivo in C57BL/6 mice with ALI induced by intratracheal injections of lipopolysaccharide (LPS) and in vitro in LPS-stimulated human umbilical vein endothelial cells. Plasma concentrations and coagulation indices were measured in mice fed normal chow or chow containing rivaroxaban (0.2 or 0.4 mg/g) for 10 days. The rivaroxaban-treated mice had significantly reduced neutrophil sequestration with preservation of the lung tissue architecture compared with that in the untreated controls. The levels of tumor necrosis factor alpha, interleukin 1 beta, and interleukin 6, as well as total protein and Evans blue concentrations, were all significantly reduced in bronchoalveolar lavage fluid from mice treated with rivaroxaban. Rivaroxaban treatment also ameliorated the LPS-induced PAR-2 increase and nuclear factor kappa B (NF-κB) activation. In vitro, cells treated with rivaroxaban had higher cell viability with an attenuation of LPS-induced increases in membrane permeability and proinflammatory cytokine levels, as well as reduced apoptosis. Furthermore, rivaroxaban inhibited the phosphorylation of TAK1 and p65. These data show that rivaroxaban attenuates ALI and inflammation by inhibiting the PAR-2/NF-κB signaling pathway.

Keywords: Acute lung injury, endothelial cells, factor Xa, NF-κB, rivaroxaban

Introduction

Acute lung injury (ALI) is a critical hypoxemic respiratory failure characterized by vascular leakage, alveolar capillary membrane damage, severe neutrophil infiltration, and pulmonary edema secondary to endothelial barrier dysfunction [1], and its underlying pathological changes include hemorrhage and microvascular thrombosis [2]. A major cause of mortality for ALI is bacterial sepsis, in which lipopolysaccharide (LPS) and the endotoxins of Gram-negative bacteria contribute to inflammation, cytoskeleton remodeling, and endothelial barrier dysfunction [3]. The pathogenesis of ALI involves inflammation and, in particular, a procoagulant antifibrinolytic environment in the alveoli and within systemic circulation [2, 4]. A previous study showed that tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β), and interleukin 6 (IL-6) increase tissue factors and inhibit fibrinolysis, thereby activating an extrinsic pathway, and that factor Xa (FXa), alpha thrombin, and fibrin increased the synthesis of IL-6 and IL-8 [5]. This “cross-talk” amplification of the coagulation and inflammatory cascades contributes to ALI [6].

Although the primary function of the coagulation cascade is to promote hemostasis and limit blood loss in response to tissue injury, it also plays a pivotal role in influencing inflammatory and repair responses to tissue injury [7]. Interestingly, bronchoalveolar lavage fluid (BALF) from mice with ALI and pulmonary fibrosis have elevated levels of thrombin and FXa [8], a serine protease that links the extrinsic and intrinsic pathways in the coagulation cas-
Factor Xa inhibition attenuates lung injury progression

cade. Recent evidence also indicates that FXa has nonhematologic functions, such as mediating inflammation, vascular remodeling, and tissue fibrosis [9, 10] and increasing the transcription of inflammatory molecules [11, 12], which enhance tissue inflammation and remodeling and are primarily mediated by protease-activated receptors (PARs) [12-14]. PARs are a small family of G protein-coupled receptors that also mediate the cellular effects of thrombin and other proteases, such as trypsin and metalloproteinase [15]. PAR-2 is predominantly expressed in endothelial cells (ECs) in the vessel wall and, when activated, facilitates their conversion to a proinflammatory phenotype and increases vascular permeability and the exposure/secretion of proteins and cytokines that promote platelet and leukocyte accumulation [16-18].

Proper lung functioning requires intact tight epithelial and endothelial barriers and normal ion and water transport, which prevents alveolar flooding [19]. ECs attach to vessel walls to regulate blood flow and the delivery of cells and proteins to tissues [20, 21]. The loss of EC barrier function is tightly linked to agonist-induced cytoskeletal reorganization, which disrupts cell-cell contacts and promotes the formation of paracellular gaps. A failure to restore EC function can lead to the destruction of the blood-air barrier, which directly results in the leakage of lung tissue protein, thus initiating ALI [22, 23]. EC dysfunction can also lead to pulmonary permeability edema, a fatal complication of ALI. Thus, therapies that preserve or restore this vascular barrier are urgently needed.

A previous report found that rivaroxaban, an approved oral anticoagulant that inhibits FXa and the prothrombinase complex, suppresses the expression of inflammatory mediators [12]. To test whether rivaroxaban inhibits inflammatory cytokine release in ECs and attenuates damage from ALI, we administered rivaroxaban to mice with LPS-mediated lung injury and to LPS-treated ECs in vitro. In addition, the mechanism by which rivaroxaban affects signal transduction in ECs was studied.

Materials and methods

Reagents

Human umbilical vein ECs (HUVECs) were purchased from IBCB (Shanghai, China). Dulbecco’s modified Eagle’s medium (DMEM) and fetal bovine serum (FBS) were from Gibco of Thermo Fisher Scientific (Shanghai, China). FXa was purchased from Hematologic Technologies, Inc. (Essex Junction, VT, USA). Bacterial LPS and Evans blue (EB) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Rivaroxaban was purchased from Janssen Pharmaceuticals (Beerse, Belgium) and processed to 0.4 mg/g and 0.2 mg/g chow in the SLAC Laboratory Animal Center (Shanghai, China). Specific monoclonal antibodies against p38, phospho-p38, JNK, phospho-JNK, p65, phospho-p65, TAK1, phospho-TAK1, and GAPDH were obtained from Cell Signaling Technology (Beverly, MA, USA). The anti-PAR-2 antibody was obtained from Abcam (Cambridge, MA, USA), and the anti-myeloperoxidase (MPO) antibody was purchased from R&D Systems, Inc. (Minneapolis, MN, USA). Enzyme-linked immunosorbent assay (ELISA) kits for measuring mouse IL-1β, IL-6, and TNF-α, as well as human IL-1β, IL-6, and TNF-α immunoassay kits, were obtained from R&D Systems, Inc. Protein concentrations were determined using the bicinchoninic acid (BCA) protein assay kit (Beyotime Institute of Biotechnology, Jiangsu, China). All other chemicals were of reagent grade.

Mice, animal sacrifice, and preparation of plasma and tissue

Male C57BL/6 mice (6 to 7 weeks old; average weight, 20 g) from the SLAC Laboratory Animal Center were used in this study. Animals were kept in a controlled environment with regulated temperature and humidity on a 12/12-h light/dark cycle with ad libitum access to chow and drinking water. Mice were fed normal chow (PBS and N-LPS groups) or chow containing rivaroxaban at 0.2 mg/g or 0.4 mg/g (L-LPS or H-LPS group, respectively) [14]. Body weights were measured just before LPS administration. Mice were anesthetized with an intraperitoneal injection of sodium pentobarbital and received intratracheal injections of either 2.5 µl/g body weight of 2 mg/ml LPS saline solution or an equivalent volume of phosphate-buffered saline (PBS) (Figure 1A). After 48 h, the mice were anesthetized for plasma, BALF, or lung histological analyses. All data represent 6 mice per group. Blood was collected in the morning, drawn from the left ventricle into 3.4% sodium citrate (9:1 ratio). Platelet-poor plasma was prepared in < 2 h via two
sequential centrifugations to remove residual platelets: citrated blood was first centrifuged at 6,000 × g for 5 min at 4°C, and the supernatant was then centrifuged at 10,000 × g for 5 min at 4°C, aliquoted, and stored at -80°C until use [24]. BALF was obtained by instilling the left lung with 500 µl of precooled PBS and gently aspirating repeatedly three times. BALF was assessed for cell counts, protein content, EB amounts, and cytokine levels. Right lung lobes were removed to obtain formalin-fixed paraffin-embedded sections. Part of the lung tissue was snap-frozen in liquid nitrogen and stored at -80°C for qPCR and Western blot analyses. All experiments were approved by the University of Fudan Animal Care and Use Committee.

Assessment of coagulation in vivo

Tail bleeding times in mice were determined by amputating the tail 5 mm from the tip and immersing it in 0.9% isotonic saline at 37°C and recording the time to a complete arrest of bleeding. Plasma was collected in tubes containing one-tenth the volume of 3.4% sodium citrate to determine the activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT) with the appropriate reagents using a semiautomated coagulation analyzer.

Plasma concentrations of rivaroxaban

Plasma concentrations of rivaroxaban were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) [25]. Linezolid was used as an internal standard, as it has structural similarities with rivaroxaban. Working solutions of 1,090 ng/ml, 545 ng/ml, 218 ng/ml, 109 ng/ml, 55 ng/ml, and 11 ng/ml rivaroxaban were obtained by mixing these stock solutions with linezolid. The concentration of dimethyl sulfoxide in plasma was 0.05%, which does not affect coagulation [26]. Sample preparation consisted of mixing methanol containing the internal standard and 100 µl of the plasma sample. The mixture was gently shaken and centrifuged. An aliquot (20 µl) of the final extract was injected into the LC-MS/MS system.

Lung wet-to-dry weight ratio

Wet-to-dry lung weight ratios were used as a measure of pulmonary edema. Mice were anesthetized, and the chest cavities were exposed. The lower lobe of the right lung of each mouse was removed and weighed on a piece of aluminum foil to determine the wet weight; the dry weight was obtained after the tissue was dried in an oven for 5 days at 60°C. The dry weights were monitored until two successive weights were similar, and the ratio was subsequently calculated as the net wet weight/net dry weight [27].

Lung permeability assessment

Lung permeability was assessed using the protein and EB dye concentrations in BALF samples and the EB dye extravasation method, as described previously [28]. Collected BALF was centrifuged at 500 × g for 10 min at 4°C, and the total protein content was measured by using a BCA protein assay kit according to the manufacturer’s instructions. EB dye concentrations in BALF samples were calculated from a standard curve and are expressed as µg/ml. EB dye binds to circulating plasma proteins.
and extravasates into the tissue at sites of increased vascular permeability [29]. For this method, EB dye at a dose of 50 mg/kg was injected into mice via the lateral tail vein 120 min before tissue collection. The left lung of each mouse was removed, and the dye was extracted in 2 ml formamide and 1 ml PBS solution at 60°C for 72 h. The optical density of the supernatant was measured at 620 nm. The results were normalized to the dry weight of the lung. The extravasated EB in lung tissue was expressed as µg of EB dye/g lung tissue.

**Inflammatory cell counts in BALF**

BALF samples were centrifuged at 500 × g for 10 min at 4°C. The cell-free supernatants were collected and frozen at -80°C for cytokine assays, and the pellets were lysed with red blood cell lysis buffer and resuspended in 100 µl PBS. Total cell counts were determined in cell suspensions using an animal blood counter. Then, 10 µl of the remaining cell suspension was used to prepare cytosmears by dripping onto glass slides. The smears were air-dried overnight prior to Giemsa-Wright staining to observe nucleated cells.

**Morphological evaluation of lung sections**

After opening the chest of each mouse, a portion of the right lung was removed, submerged and fixed in 10% buffered formalin, embedded in paraffin wax, and sectioned at 4 µm. Sections were stained with hematoxylin and eosin to semiquantitatively assess the severity of lung injury according to previously described methods with slight modifications. All histologic examinations were carried out in a double-blind manner using five images from each sample taken under × 100 magnification. The following pathological features were determined: i) focal alveolar membrane thickening; ii) capillary congestion; iii) intra-alveolar hemorrhage, iv) interstitial neutrophil infiltration, and v) intra-alveolar neutrophil infiltration. Each feature was scored from 0 to 3 on the basis of its absence (0) or presence to a mild (1), moderate (2), or severe (3) degree, and a cumulative total histology score was determined. The scores for each parameter from five images were averaged to obtain the mean for each sample.

**Radiological analysis**

To evaluate ALI, micro-computed tomography (micro-CT) high-spatial-resolution images were obtained of the entire thorax after 48 h of LPS administration. The mice were anesthetized and placed in the micro-CT chamber in the supine position. CT images were collected on a volumetric Siemens Inveon micro-CT scanner (Siemens, Germany) at 70 kVp and 500 µA. Images were acquired at 1,300 ms/frame, and 360° views and were reconstructed using the Feldkamp algorithm. The reconstructed images were 2,048 × 2,048 pixels, and the effective pixel size was 39.99 µm. The final reconstructed data were converted to the Digital Imaging and Communications in Medicine (DICOM) format by software (Lucion; Mevisys, Seoul, South Korea).

**Immunohistochemistry**

Mouse lungs were embedded in paraffin, and 4-µm serial sections (300 µm apart) were obtained. For immunohistochemistry, paraffin sections were dewaxed, hydrated through a descending ethanol series, washed in 0.05 M Tris-HCl buffer (pH 7.6), placed in boiling citrate buffer (pH 5.8) for 10 min, and then allowed to cool at room temperature (RT) for 20 min. They were rinsed 3 × in Tris-buffered saline (pH 7.8) for 4 min each. Slides were placed in 50 ml of 0.5% trypsin solution, incubated in a water bath at 37°C for 15 min, and then rinsed 2 × in Tris-HCl buffer (pH 7.8) for 4 min each. The slides were then washed 2 × in PBS (pH 7.6) for 4 min each and blocked in 10% lamb serum for 30 min at RT before incubating with primary antibody overnight at 4°C. After three washes with PBS for 15 min, secondary antibodies were applied for 20 min at 37°C.

**Cell culture and LPS treatment**

HUVECs were maintained in DMEM supplemented with 1% penicillin/streptomycin and 10% FBS in an atmosphere of 5% CO₂ at 37°C and routinely passaged every 3 days. For analysis of the effect of rivaroxaban on proinflammatory activation, HUVECs were spread onto 100-mm or 60-mm tissue culture plates, grown to approximately 80% confluence, and treated with FXa (100 nM) with/without rivaroxaban (1,000 nM) for 24 h in serum-starved...
Factor Xa inhibition attenuates lung injury progression

and heparin-free conditioned medium. Then, some of the HUVEC monolayers were exposed to LPS (100 ng/ml) for 16 h. HUVECs were randomly divided into four groups as follows (Figure 1B): control group, cells were cultured in DMEM without serum, FXa, rivaroxaban, or LPS; LPS group, cells were cultured with LPS (100 ng/ml) for 16 h; FXa + LPS group, cells were cultured in serum-starved DMEM with FXa for 24 h before LPS was added; FXa + Riv + LPS group, cells were cultured in serum-starved DMEM with FXa and rivaroxaban for 24 h before LPS was added. After a 16-h treatment period, the cells and medium were collected for further experiments.

**CCK-8 assay**

Cells were separately seeded into four 96-well plates at a density of 1 × 10⁴ cells with 100 µl medium in each well and incubated for 24 h in an atmosphere of 5% CO₂ at 37°C. To measure cell proliferation, 10 µl of the CCK-8 assay solution was added to each well, and the optical density at 450 nm was measured with a microplate reader after 2 h of incubation.

**Wound healing assay**

A wound healing assay was carried out to measure the motility of vascular ECs after treatment with rivaroxaban [30]. Briefly, 1 × 10⁵ cells were seeded on 12-well plates and cultured for 48 h until full confluence was reached. After FXa and rivaroxaban pretreatment, the wells were then washed with PBS to remove nonadherent cells, and the cells in the middle of each well were scraped linearly with a 10-µl sterilized plastic pipette tip and induced with 100 ng/ml LPS for 16 h. The horizontal distance between the sides of the wound was photographed and measured with a digital microscope; data from three wells were averaged and experiments were performed in triplicates.

**Annexin V-fluorescein isothiocyanate/propidium iodide (PI) staining for apoptosis determination**

Apoptosis of HUVECs was assessed by flow cytometry. Briefly, trypsinized cells were washed with precooled PBS and incubated in the dark for 20 min at 4°C in 100 µl binding buffer containing 5 µl of Annexin V-fluorescein isothiocyanate. Next, the cells were stained with 3 µl of PI for 10 min. Fluorescence was determined by flow cytometry using CellQuest 5.1 software (BD Biosciences), and the data were analyzed with FlowJo software (Tree Star Inc., Ashland, OR, USA). The results were converted into percentages according to fluorescence intensity of the medium.

**Endothelial permeability assay in vitro**

Endothelial monolayer permeability assays were performed by measuring the flux of albumin-bound EB across functional HUVEC monolayers grown on Transwell polycarbonate membranes, as described previously [31, 32]. Briefly, a cell suspension (2 × 10⁵ cells) was added to the upper chambers of the Transwell apparatus and cultured with 10% FBS DMEM overnight. After changing to serum-free medium, the HUVECs were exposed to FXa with or without rivaroxaban for 24 h followed by LPS (final concentration, 100 ng/ml) for 16 h. Next, 100 µl medium containing EB-conjugated bovine serum albumin (final concentration 0.67 mg/ml) was added to the Transwell inserts, while 600 µl medium containing 4% bovine serum albumin was added to the lower chamber. After incubation at 37°C for 1 h, the absorbance at 620 nm of 100 µl of medium from the lower chamber was measured.

**Measurement of cytokines in HUVEC medium and BALF**

HUVECs were grown to 80-90% confluence before treatment per the experimental conditions. To assess proinflammatory cytokine secretion, the supernatants were briefly centrifuged for 10 min at 500 × g to remove cell debris, the concentrations of TNF-a, IL-1β, and IL-6 were measured with commercially available human ELISA kits according to the manufacturer’s instructions. In the animal studies, the analysis of TNF-a, IL-1β, and IL-6 in BALF supernatants was performed with mouse cytokine kits, according to the manufacturer’s instructions.

**Western blot analysis**

Frozen lung tissues were homogenized and lysed in RIPA buffer. HUVECs were lysed using ice-cold RIPA buffer and protease inhibitor cocktail. Proteins were extracted by centrifugation at 14,000 × g for 5 min at 4°C, and the
protein concentrations were measured with a BCA protein assay kit. Samples of cell/tissue protein were mixed with loading buffer and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins were then transferred to polyvinylidene fluoride membranes by electrotransfer and blocked with 5% skim milk and 0.1% Tween 20 in PBS at RT for 2 h. The membranes were incubated with primary antibodies overnight at 4°C and then with horseradish peroxidase-conjugated secondary antibodies (1:1,000) at RT for 1.5 h. Images of protein bands were captured by a gel imaging system. The ratio of gray-scale values between the target protein band and the internal reference (β-actin or GAPDH) band was calculated as the relative protein expression using ImageJ.

Statistical analysis

All data were analyzed with GraphPad Prism 6 software (GraphPad Software Inc., La Jolla, CA, USA). The distance of cell migration and Western blot band intensities were measured using Image-Pro Plus 6 software (Media Cybernetics, Inc., Rockville, MD). One-way analyses of variance or the Student’s t tests was used to compare data among or between groups, respectively. Pearson’s X² or Fisher’s exact tests were used to compare the percentages of apoptotic cells, the ratios of protein band intensities, and lung injury scores. For all tests, P values of < 0.05 were considered statistically significant.

Results

Baseline characteristics of mice with ALI

There were no notable differences among mice fed normal chow or those fed chow containing rivaroxaban with regard to body weight (Figure 2A) or average tail bleeding time (P = 0.30) (Figure 2B). As expected, the plasma concentration of rivaroxaban was significantly higher in
mice fed chow containing 0.2 or 0.4 mg of rivaroxaban/g than in normal chow-fed controls (Figure 2C). Because mice are nocturnal, all measurements were performed in the morning to minimize the variability in the plasma drug levels due to differences in chow consumption. Although there was no difference among the groups with regard to TT and APTT values (P > 0.05), PT was significantly longer in mice fed chow containing 0.4 mg/g rivaroxaban (P < 0.01) (Figure 2D-F).

Rivaroxaban attenuates LPS-induced ALI in mice

To assess the effects of rivaroxaban on lung pathology, lung tissues from mice 48 h after a challenge with LPS were stained with hematoxylin and eosin (Figure 3A). According to the total histology scores, high-dose rivaroxaban reduced LPS-induced injury in the lungs compared with that in mice fed the normal diet, though the damage remained greater than that in sham-operated animals; however, low-dose rivaroxaban did not significantly alleviate injury (Figure 3B). Lung injury was also assessed by micro-CT, which revealed bilateral patchy infiltrates in LPS-treated mice (Figure 3C), in contrast to the normal radiological appearance of the lungs of mice in the control group. Infiltrates and injury were alleviated in the lungs of the rivaroxaban-treated mice.

Effects of rivaroxaban on cell viability, apoptosis, and migration of LPS-treated HUVECs

The effect of rivaroxaban on the viability of LPS-treated HUVECs was assessed with CCK8 cell
Factor Xa inhibition attenuates lung injury progression

viability kits. As shown in Figure 4A, cell viability was significantly decreased by exposure to LPS, and viability further decreased with FXa treatment, compared with that of the untreated control group. However, these decreases were attenuated with rivaroxaban, suggesting that the drug protects HUVECs against LPS-induced injury in vitro. As apoptosis also contributes to ALI/acute respiratory distress syndrome (ARDS) pathogenesis, flow cytometry was performed with Annexin V-PI double-stained HUVECs (Figure 4B). As shown in Figure 4C, LPS exposure significantly increased the percentage of apoptotic cells compared with that in the untreated control group, and this effect was significantly attenuated in cells pretreated with rivaroxaban. The highest percentage of apoptotic cells was observed in HUVECs treated with LPS, which was not significantly different from that of HUVECs treated with LPS and FXa. Next, the effect of rivaroxaban on LPS-induced HUVEC migration was assessed. As shown in Figure 4D and 4E, stimulation of HUVECs with 100 ng/ml LPS for 16 h significantly spurred cell migration (2.17-fold vs control, P < 0.01). The migration of cells pretreated with FXa and rivaroxaban was decreased compared to that of cells treated with LPS alone (1.78-fold of...
Factor Xa inhibition attenuates lung injury progression

the untreated group, \( P < 0.05 \)). These results demonstrate that rivaroxaban significantly retarded HUVEC migration.

**Rivaroxaban decreases LPS-induced vascular endothelial barrier permeability in vivo and in vitro**

The wet-to-dry ratio of lung tissue weight was 4.3 ± 0.11 in mice in the PBS group and increased to 5.29 ± 0.25 in mice in the LPS group fed normal standard chow (N-LPS), which indicates there was fluid accumulation in the lungs (Figure 5A). However, the ratios did not differ between the LPS-treated animals fed normal chow and those fed rivaroxaban-containing chow. The albumin concentration in BALF represents the level of the effused albumin, and it was much higher in the LPS groups than in the PBS-treated group (\( P < 0.05 \)). However, treatment with rivaroxaban (0.2 mg/g chow or 0.4 mg/g chow) substantially decreased the concentration of albumin in BALF (Figure 5B). To further assess EC barrier dysfunction, EB dye was injected via the caudal veins of mice 48 h after their LPS challenge, and EB extravasation in the BALF and lung tissue was determined 2 h later (Figure 5C and 5D). Extravasation of EB was significantly higher in the LPS groups than in the PBS group (\( P < 0.05 \)) but was significantly decreased in LPS-treated mice fed rivaroxaban-containing chow (\( P < 0.05 \) vs N-LPS group). Similarly, LPS induced the transendothelial transport of albumin-bound EB across an EC monolayer in vitro, whereas cells pretreated with rivaroxaban showed decreased EB transport (Figure 5E). Altogether, these observations strongly indicate that rivaroxaban protects ECs in vitro and may be protective against ALI in vivo.

**Rivaroxaban suppresses inflammatory responses to LPS-induced ALI in vivo and in vitro**

LPS elicits a robust inflammatory response and produces various effects linked to ALI. To determine whether the rivaroxaban-mediated protection against barrier dysfunction occurs due to the inhibition of inflammatory mediators affecting barrier integrity, we assessed the pro-
Factor Xa inhibition attenuates lung injury progression

The numbers of inflammatory cells in BALF samples increased dramatically (~8-fold) in response to LPS stimulation (Figure 6A). However, the total number of BALF cells significantly decreased by
Rivaroxaban suppresses activation of the NF-κB pathway by PAR-2 following ALI in vivo and in vitro

To identify possible mechanisms underlying the protective effect of rivaroxaban on ALI, we examined the expression of PAR-2 in lung tissues. Immunohistochemical and Western blot analyses of lung tissues showed significantly increased expression of PAR-2 in LPS-treated mice, which was significantly decreased by treatment with rivaroxaban (Figure 7A-C). Together with the above results, the findings suggest that PAR-2 and its ligand FXa play a role in ALI pathogenesis. As coagulation factor VIIa/FXa-PAR-2 signaling activates NF-κB and MAPKs, which are major mediators of inflammation [9, 18, 33], we next examined whether the activation of these signaling pathways was involved. We found that LPS stimulation strongly induced the phosphorylation of the p65 NF-κB subunit in mouse lung tissue (Figure 7D). To explore this activation in more detail, we measured the phosphorylation of various signaling components in HUVECs stimulated with LPS in vitro. The pretreatment of HUVECs with FXa and its selective inhibitor rivaroxaban did not significantly suppress the LPS-induced phosphorylation of the MAPK proteins JNK and p38 (Figure 7E-G) but did significantly decrease the LPS-induced phosphorylation of TAK1 and p65 (Figure 7E, 7H, and 7I). These results suggest that rivaroxaban activates the TAK1 and p65 NF-κB signaling pathways via PAR-2 in LPS-induced ALI.

Discussion

Progressive ARDS is closely linked with inflammation and coagulation, which can be triggered by various coagulation proteases, such as FXa and thrombin [34]. Further elucidation of the subtle cross-talk between these processes may provide opportunities for unique therapeutic interventions in patients with ALI. In the present research, a direct inhibitor of FXa produced beneficial effects in a mouse model of ALI/ARDS, generated via intratracheal administration of LPS, and in HUVECs. Although LPS did not alter coagulation in mice, as assessed by APTT, TT, and PT (a measure of FII, FV, FX, and FVII activities), which is similar to previous results [7.5], the inhibition of FXa with rivaroxaban (0.4 mg/g chow) prolonged PT. Moreover, this dose of rivaroxaban (or 1 µM in vitro) ameliorated ALI and EC injury and dysfunction with concomitant reductions in inflammatory mediators. These effects were associated with decreased PAR-2 expression and activation of the NF-κB signaling pathway (Figure 8). Thus, rivaroxaban has anticoagulant effects and inhibits inflammatory responses in LPS-induced ALI.

Rivaroxaban, an orally administered FXa inhibitor, has been undergoing extensive clinical evaluations for the prevention and treatment of thromboembolic disorders. The high dose of rivaroxaban used in mice in the present study resulted in plasma levels of 141 ng/ml. In this study, this dose reduced not only the levels of inflammatory cytokines in BALF but also ALI progression, suggesting that rivaroxaban may prevent the development of lung injury via the inhibition of inflammatory activation.
Factor Xa inhibition attenuates lung injury progression

Figure 7. Effect of rivaroxaban on LPS-induced PAR-2 expression and signaling pathway activation in vivo and in vitro. (A) Immunohistochemical staining of PAR-2 in lung tissue (×100 and ×400 [insets] magnification). (B) Western blot analysis of PAR-2, phospho-p65 (P-p65), and p65 NF-κB protein expression in lung tissue samples. Membrane probing with β-actin was used for normalization. Quantification of PAR-2 (C) and P-p65 (D) expression by ImageJ software. Data are the means ± SEMs (n=6). *P < 0.05 vs PBS group; #P < 0.05 vs N–LPS group. (E) Representative Western blots for MAPK and NF-κB signaling in HUVECs. Quantification of P-JNK (F), P-p38 (G), P-TAK1 (H), and P-p65 (I) expression. Data are the means ± SEMs (n=3). *P < 0.05 vs untreated controls; #P < 0.05 vs LPS–treated group.
Vascular EC injury and hyperpermeability play important roles in the development of LPS-induced ALI. These changes promote the release of cytokines and inflammatory responses, thereby exacerbating ARDS [35]. At the same time, the inflammatory cytokines promote leukocyte adhesion and coagulation activation and increase vascular permeability. Thus, the maintenance of endothelial barrier integrity is essential for vascular and tissue homeostasis [36]. In the present study, we found that LPS increased lung vascular endothelial permeability by altering the paracellular and transcellular barriers. Moreover, rivaroxaban reduced the albumin-bound EB content in the lower chamber of the Transwell assay, thereby retaining the integrity of the EC monolayer. Rivaroxaban also inhibited EC apoptosis, which plays an important role in various inflammatory diseases, and decreased the release of inflammatory cytokines. These results suggest that controlling inflammation at the level of ECs may efficiently retard or reverse the pathogenetic process in ALI. Therefore, understanding the differences among the signaling pathways of inflammatory factors is indispensable.

PAR-2 is activated by the tissue factor-coagulation factor VIIa complex and coagulation FXa and has crucial roles in inflammation and the regulation of vascular function. ECs highly express PAR-2 in response to inflammation, and PAR-2 stimulates cytokine release in HUVECs [18, 37, 38]. We demonstrated that LPS activates PAR-2 and promotes the production of cytokines in mice with ALI, which were suppressed by the inhibition of FXa with rivaroxaban. Previous studies have also demonstrated that coagulation factor VIIa/FXa-PAR-2 signaling activates NF-κB and MAPK, which are important regulators of cytokine production and are associated with the pathogenesis of inflammatory processes [9, 11, 38, 39]. Our results showed that these were activated by LPS and that pharmacologic pretreatment with rivaroxaban significantly attenuated NF-κB activation. Thus, the protection against LPS-induced lung injury both in vivo and in vitro may involve the inhibition of PAR-2 activity and NF-κB signaling, particularly via p65 phosphorylation. Altogether, these data suggest that rivaroxaban may be a new therapeutic option to relieve ALI via the suppression of PAR-2-NF-κB signaling and inflammation.

In conclusion, the present study demonstrates that in mouse lung tissue, FXa is an important coagulant factor and a mediator of inflammatory signaling via the activation of PAR-2 and NF-κB. LPS in lung tissue induces ALI by generating an inflammatory prothrombotic state. Importantly, LPS-induced inflammatory signaling and vascular EC activation can be substantially attenuated by an FXa antagonist and anticoagulant, rivaroxaban. Thus, rivaroxaban represents a novel therapeutic strategy to prevent and/or reduce the progression of ALI.

Acknowledgements

This study was supported by the Natural Science Foundation of China (81490533, 81400018, 81570028, 81500026, 81770039), the State Key Basic Research Program (973) project (2015CB553404), the Shanghai Science and Technology Committee (18140903400, 15DZ1930600, 15DZ1941103), and the Shanghai Three-Year Plan of the Key
Factor Xa inhibition attenuates lung injury progression

Subjects Construction in Public Health-Infectious Diseases and Pathogenic Microorganism (15GWZK0102).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Xiaofeng Chen, Department of Cardiothoracic Surgery, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Street, Shanghai 200040, China. Tel: 086-021-52887075; E-mail: hs_chenxiaofeng@yeah.net; Dr. Jie Hu, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, 108 Fenglin Road, Xuhui District, Shanghai 200040, China. Tel: 086-021-64041990; E-mail: huashan_heart@sina.cn

References


Factor Xa inhibition attenuates lung injury progression.


